Alexza Pharmaceuticals to Present at the 2013 Wedbush Life Sciences Management Access Conference

Alexza Pharmaceuticals to Present at the 2013 Wedbush Life Sciences Management
                              Access Conference

PR Newswire

MOUNTAIN VIEW, Calif., Aug. 6, 2013

MOUNTAIN VIEW, Calif., Aug. 6, 2013 /PRNewswire/ --Alexza Pharmaceuticals,
Inc. (Nasdaq: ALXA) announced today that the Company will participate in the
2013 Wedbush Life Sciences Management Access Conference, being held in New
York, New York, August 13 - 14, 2013. Thomas B. King, Alexza President and
CEO, will present at the conference. The Alexza corporate presentation will
be Wednesday, August 14, 2013 at 8:35 a.m. Eastern Time. The presentation
will be webcast live.

To access the presentation via the Web, please go to the Alexza Investor
Relations tab at www.alexza.com or directly
http://wsw.com/webcast/wedbush25/ALXA. A replay of the webcast will be
available approximately 24 hours after the presentation and archived for 30
days.

About Alexza Pharmaceuticals, Inc.
Alexza Pharmaceuticals is focused on the research, development and
commercialization of novel, proprietary products for the acute treatment of
central nervous system conditions, including agitation, acute repetitive
seizures and insomnia. Alexza's products are based on the Staccato^® system,
a hand-held inhaler designed to deliver a drug aerosol to the deep lung,
providing rapid systemic delivery and therapeutic onset, in a simple,
non-invasive manner.

ADASUVE^® (Staccato loxapine), Alexza's first approved product, was approved
by the U.S. Food and Drug Administration in December 2012 and by the European
Medicines Agency in February 2013. Teva Pharmaceutical USA Inc. is Alexza's
commercial partner for ADASUVE in the U.S. Grupo Ferrer Internacional, S.A.
is Alexza's commercial partner for ADASUVE in Europe, Latin America, Russia
and the Commonwealth of Independent States countries.

For more information about Alexza, the Staccato system technology or the
Company's development programs, please visit www.alexza.com. For more
information about ADASUVE, please visit www.adasuve.com.

ADASUVE^® and Staccato^® are registered trademarks of Alexza Pharmaceuticals,
Inc.

Safe Harbor Statement
The anticipated presentation will contain forward-looking statements that
involve significant risks and uncertainties. Any statement describing the
Company's expectations or beliefs is a forward-looking statement, as defined
in the Private Securities Litigation Reform Act of 1995, and should be
considered an at-risk statement. Such statements are subject to certain risks
and uncertainties, particularly those inherent in the process of developing
and commercializing drugs, including the ability for Alexza and our partners,
Teva and Ferrer, to effectively and profitably commercialize ADASUVE,
estimated product revenues and royalties associated with the sale of ADASUVE,
the adequacy of the Company's capital to support the Company's operations, and
the Company's ability to raise additional funds and the potential terms of
such potential financings. The Company's forward-looking statements also
involve assumptions that, if they prove incorrect, would cause its results to
differ materially from those expressed or implied by such forward-looking
statements. These and other risks concerning Alexza's business are described
in additional detail in the Company's Annual Report on Form 10-K for the year
ended December 31, 2012 and the Company's other Periodic and Current Reports
filed with the Securities and Exchange Commission. Forward-looking statements
contained in this announcement are made as of this date, and the Company
undertakes no obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or otherwise.

SOURCE Alexza Pharmaceuticals, Inc.

Website: http://www.alexza.com
Contact: BCC Partners, Karen L. Bergman and Michelle Corral, +1-650-575-1509
or +1-415-794-8662, kbergman@bccpartners.com or mcorral@bccpartners.com
 
Press spacebar to pause and continue. Press esc to stop.